PICOT increases cardiac contractility by inhibiting PKCζ activity

Journal of Molecular and Cellular Cardiology

Volumn 53, Issue 1, 2012, Pages 53-63

  Oh, Jae Gyun ^a   Jeong, Dongtak ^b   Cha, Hyeseon ^a   Kim, Ji Myoung ^a   Lifirsu, Ekaterina ^a   Kim, Jihwa ^a   Yang, Dong Kwon ^a   Park, Chang Sik ^a   Kho, Changwon ^b   Park, Soonyong ^a   Yoo, Yung Joon ^a   Kim, Do Han ^a   Kim, Jaetaek ^c   Hajjar, Roger J ^b   Park, Woo Jin ^a  

^a Gwangju Institute of Science and Technology (GIST)   (South Korea)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Chung Ang University   (South Korea)

Author keywords

Contractility; PICOT; PKC ; PKC ; PP2A

Indexed keywords

MEMBRANE PROTEIN; PHOSPHOLAMBAN; PROTEIN KINASE C ALPHA; PROTEIN KINASE C INTERACTING COUSIN OF THIOREDOXIN; PROTEIN KINASE C ZETA; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; TROPONIN I; TROPONIN T; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOTINYLATION; CALCIUM TRANSPORT; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; GENE OVEREXPRESSION; HEART HEMODYNAMICS; HEART MUSCLE CONTRACTILITY; IMMUNOPRECIPITATION; INOTROPISM; MORPHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; RAT; SIGNAL TRANSDUCTION; TRANSGENE; UPREGULATION;

ANIMALS; CALCIUM-BINDING PROTEINS; CARRIER PROTEINS; CELL LINE; ENZYME ACTIVATION; HUMANS; MALE; MICE; MODELS, BIOLOGICAL; MYOCARDIAL CONTRACTION; PEPTIDE FRAGMENTS; PROTEIN BINDING; PROTEIN KINASE C; PROTEIN KINASE C-ALPHA; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TROPONIN I; TROPONIN T;

ADENO-ASSOCIATED VIRUS;

EID: 84861964070     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2012.03.005     Document Type: Article

References (54)

1. Lopez A.D., Mathers C.D., Ezzati M., Jamison D.T., Murray C.J. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet May 27 2006, 367(9524):1747-1757.
2. Mathers C.D., Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med Nov 2006, 3(11):e442.
3. Mathers C.D., Boerma T., Ma Fat D. Global and regional causes of death. Br Med Bull 2009, 92:7-32.
4. Houser S.R., Margulies K.B. Is depressed myocyte contractility centrally involved in heart failure?. Circ Res Mar 7 2003, 92(4):350-358.
5. Arai M., Matsui H., Periasamy M. Sarcoplasmic reticulum gene expression in cardiac hypertrophy and heart failure. Circ Res Apr 1994, 74(4):555-564.
6. Miyamoto M.I., del Monte F., Schmidt U., DiSalvo T.S., Kang Z.B., Matsui T., et al. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci U S A Jan 18 2000, 97(2):793-798.
7. del Monte F., Hajjar R.J., Harding S.E. Overwhelming evidence of the beneficial effects of SERCA gene transfer in heart failure. Circ Res Jun 8 2001, 88(11):E66-E67.
8. Sakata S., Lebeche D., Sakata Y., Sakata N., Chemaly E.R., Liang L., et al. Transcoronary gene transfer of SERCA2a increases coronary blood flow and decreases cardiomyocyte size in a type 2 diabetic rat model. Am J Physiol Heart Circ Physiol Feb 2007, 292(2):H1204-H1207.
9. Kawase Y., Ly H.Q., Prunier F., Lebeche D., Shi Y., Jin H., et al. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol Mar 18 2008, 51(11):1112-1119.
10. Jaski B.E., Jessup M.L., Mancini D.M., Cappola T.P., Pauly D.F., Greenberg B., et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail Apr 2009, 15(3):171-181.
11. 2+-ATPase in patients with advanced heart failure. Circulation Jul 19 2011, 124(3):304-313.
12. Braz J.C., Gregory K., Pathak A., Zhao W., Sahin B., Klevitsky R., et al. PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med Mar 2004, 10(3):248-254.
13. Hambleton M., Hahn H., Pleger S.T., Kuhn M.C., Klevitsky R., Carr A.N., et al. Pharmacological- and gene therapy-based inhibition of protein kinase Calpha/beta enhances cardiac contractility and attenuates heart failure. Circulation Aug 8 2006, 114(6):574-582.
14. Liu Q., Chen X., Macdonnell S.M., Kranias E.G., Lorenz J.N., Leitges M., et al. Protein kinase C{alpha}, but not PKC{beta} or PKC{gamma}, regulates contractility and heart failure susceptibility: implications for ruboxistaurin as a novel therapeutic approach. Circ Res Jul 17 2009, 105(2):194-200.
15. Witte S., Villalba M., Bi K., Liu Y., Isakov N., Altman A. Inhibition of the c-Jun N-terminal kinase/AP-1 and NF-kappaB pathways by PICOT, a novel protein kinase C-interacting protein with a thioredoxin homology domain. J Biol Chem Jan 21 2000, 275(3):1902-1909.
16. Muhlenhoff U., Molik S., Godoy J.R., Uzarska M.A., Richter N., Seubert A., et al. Cytosolic monothiol glutaredoxins function in intracellular iron sensing and trafficking via their bound iron-sulfur cluster. Cell Metab Oct 6 2010, 12(4):373-385.
17. Jeong D., Cha H., Kim E., Kang M., Yang D.K., Kim J.M., et al. PICOT inhibits cardiac hypertrophy and enhances ventricular function and cardiomyocyte contractility. Circ Res Aug 4 2006, 99(3):307-314.
18. Cha H., Kim J.M., Oh J.G., Jeong M.H., Park C.S., Park J., et al. PICOT is a critical regulator of cardiac hypertrophy and cardiomyocyte contractility. J Mol Cell Cardiol Dec 2008, 45(6):796-803.
19. Heineke J., Ruetten H., Willenbockel C., Gross S.C., Naguib M., Schaefer A., et al. Attenuation of cardiac remodeling after myocardial infarction by muscle LIM protein-calcineurin signaling at the sarcomeric Z-disc. Proc Natl Acad Sci U S A Feb 1 2005, 102(5):1655-1660.
20. Jeong D., Kim J.M., Cha H., Oh J.G., Park J., Yun S.H., et al. PICOT attenuates cardiac hypertrophy by disrupting calcineurin-NFAT signaling. Circ Res Mar 28 2008, 102(6):711-719.
21. Ren J., Wold L.E. Measurement of Cardiac Mechanical Function in Isolated Ventricular Myocytes from Rats and Mice by Computerized Video-Based Imaging. Biol Proced Online Dec 11 2001, 3:43-53.
22. Zhou Y.Y., Wang S.Q., Zhu W.Z., Chruscinski A., Kobilka B.K., Ziman B., et al. Culture and adenoviral infection of adult mouse cardiac myocytes: methods for cellular genetic physiology. Am J Physiol Heart Circ Physiol Jul 2000, 279(1):H429-H436.
23. Luo W., Grupp I.L., Harrer J., Ponniah S., Grupp G., Duffy J.J., et al. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ Res Sep 1994, 75(3):401-409.
24. Liao P., Georgakopoulos D., Kovacs A., Zheng M., Lerner D., Pu H., et al. The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. Proc Natl Acad Sci U S A Oct 9 2001, 98(21):12283-12288.
25. Sohal D.S., Nghiem M., Crackower M.A., Witt S.A., Kimball T.R., Tymitz K.M., et al. Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein. Circ Res Jul 6 2001, 89(1):20-25.
26. Zolotukhin S., Byrne B.J., Mason E., Zolotukhin I., Potter M., Chesnut K., et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther Jun 1999, 6(6):973-985.
27. Pacher P., Nagayama T., Mukhopadhyay P., Batkai S., Kass D.A. Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc 2008, 3(9):1422-1434.
28. Porterfield J.E., Kottam A.T., Raghavan K., Escobedo D., Jenkins J.T., Larson E.R., et al. Dynamic correction for parallel conductance, GP, and gain factor, alpha, in invasive murine left ventricular volume measurements. J Appl Physiol Dec 2009, 107(6):1693-1703.
29. Berra E., Diaz-Meco M.T., Dominguez I., Municio M.M., Sanz L., Lozano J., et al. Protein kinase C zeta isoform is critical for mitogenic signal transduction. Cell Aug 13 1993, 74(3):555-563.
30. Westfall M.V., Borton A.R. Role of troponin I phosphorylation in protein kinase C-mediated enhanced contractile performance of rat myocytes. J Biol Chem Sep 5 2003, 278(36):33694-33700.
31. Sakthivel S., Finley N.L., Rosevear P.R., Lorenz J.N., Gulick J., Kim S., et al. In vivo and in vitro analysis of cardiac troponin I phosphorylation. J Biol Chem Jan 7 2005, 280(1):703-714.
32. Ke Y., Lei M., Solaro R.J. Regulation of cardiac excitation and contraction by p21 activated kinase-1. Prog Biophys Mol Biol Oct-Nov 2008, 98(2-3):238-250.
33. Ai X., Pogwizd S.M. Connexin 43 downregulation and dephosphorylation in nonischemic heart failure is associated with enhanced colocalized protein phosphatase type 2A. Circ Res 2005, 96(1):54-63.
34. Larsen K.O., Lygren B., Sjaastad I., Krobert K.A., Arnkvaern K., Florholmen G., et al. Diastolic dysfunction in alveolar hypoxia: a role for interleukin-18-mediated increase in protein phosphatase 2A. Cardiovasc Res 2008, 80(1):47-54.
35. Gergs U., Boknik P., Buchwalow I., Fabritz L., Matus M., Justus I., et al. Overexpression of the catalytic subunit of protein phosphatase 2A impairs cardiac function. J Biol Chem 2004, 279(39):40827-40834.
36. Wu S.C., Solaro R.J. Protein kinase C zeta. A novel regulator of both phosphorylation and de-phosphorylation of cardiac sarcomeric proteins. J Biol Chem 2007, 282(42):30691-30698.
37. Shin H.G., Barnett J.V., Chang P., Reddy S., Drinkwater D.C., Pierson R.N., et al. Molecular heterogeneity of protein kinase C expression in human ventricle. Cardiovasc Res 2000, 48(2):285-299.
38. Wang J., Liu X., Sentex E., Takeda N., Dhalla N.S. Increased expression of protein kinase C isoforms in heart failure due to myocardial infarction. Am J Physiol Heart Circ Physiol 2003, 284(6):H2277-H2287.
39. Simonis G., Briem S.K., Schoen S.P., Bock M., Marquetant R., Strasser R.H. Protein kinase C in the human heart: differential regulation of the isoforms in aortic stenosis or dilated cardiomyopathy. Mol Cell Biochem 2007, 305(1-2):103-111.
40. Watson J.A., Rumsby M.G., Wolowacz R.G. Phage display identifies thioredoxin and superoxide dismutase as novel protein kinase C-interacting proteins: thioredoxin inhibits protein kinase C-mediated phosphorylation of histone. Biochem J 1999, 343(Pt 2):301-305.
41. Cazaubon S., Bornancin F., Parker P.J. Threonine-497 is a critical site for permissive activation of protein kinase C alpha. Biochem J 1994, 301(Pt 2):443-448.
42. Bornancin F., Parker P.J. Phosphorylation of threonine 638 critically controls the dephosphorylation and inactivation of protein kinase Calpha. Curr Biol 1996, 6(9):1114-1123.
43. Bornancin F., Parker P.J. Phosphorylation of protein kinase C-alpha on serine 657 controls the accumulation of active enzyme and contributes to its phosphatase-resistant state. J Biol Chem 1997, 272(6):3544-3549.
44. Ziegler W.H., Parekh D.B., Le Good J.A., Whelan R.D., Kelly J.J., Frech M., et al. Rapamycin-sensitive phosphorylation of PKC on a carboxy-terminal site by an atypical PKC complex. Curr Biol 1999, 9(10):522-529.
45. Layland J., Solaro R.J., Shah A.M. Regulation of cardiac contractile function by troponin I phosphorylation. Cardiovasc Res 2005, 66(1):12-21.
46. Kentish J.C., McCloskey D.T., Layland J., Palmer S., Leiden J.M., Martin A.F., et al. Phosphorylation of troponin I by protein kinase A accelerates relaxation and crossbridge cycle kinetics in mouse ventricular muscle. Circ Res 2001, 88(10):1059-1065.
47. Pi Y., Zhang D., Kemnitz K.R., Wang H., Walker J.W. Protein kinase C and A sites on troponin I regulate myofilament Ca2+ sensitivity and ATPase activity in the mouse myocardium. J Physiol 2003, 552(Pt 3):845-857.
48. Buscemi N., Foster D.B., Neverova I., Van Eyk J.E. p21-activated kinase increases the calcium sensitivity of rat triton-skinned cardiac muscle fiber bundles via a mechanism potentially involving novel phosphorylation of troponin I. Circ Res 2002, 91(6):509-516.
49. Sumandea M.P., Pyle W.G., Kobayashi T., de Tombe P.P., Solaro R.J. Identification of a functionally critical protein kinase C phosphorylation residue of cardiac troponin T. J Biol Chem 2003, 278(37):35135-35144.
50. Packer M., Carver J.R., Rodeheffer R.J., Ivanhoe R.J., DiBianco R., Zeldis S.M., et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991, 325(21):1468-1475.
51. Cohn J.N., Goldstein S.O., Greenberg B.H., Lorell B.H., Bourge R.C., Jaski B.E., et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med 1998, 339(25):1810-1816.
52. Zimmermann N., Boknik P., Gams E., Herzig J.W., Neumann J., Scholz H. Calcium sensitization as new principle of inotropic therapy in end-stage heart failure?. Eur J Cardiothorac Surg 1998, 14(1):70-75.
53. Gheorghiade M., Teerlink J.R., Mebazaa A. Pharmacology of new agents for acute heart failure syndromes. Am J Cardiol 2005, 96(6A):68G-73G.
54. Perrone S.V., Kaplinsky E.J. Calcium sensitizer agents: a new class of inotropic agents in the treatment of decompensated heart failure. Int J Cardiol 2005, 103(3):248-255.